PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis
Juntao Feng, Xiaomei Qin, Xiaoliang Mo · 2026
Read PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis by Juntao Feng, Xiaomei Qin, Xiaoliang Mo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13630527.txt.
Description
Juntao Feng and co-authors update a systematic review and network meta-analysis of PARP inhibitor maintenance therapy for advanced ovarian cancer. Their paper deals with first-line care after a new finding.
PARP inhibitor maintenance is now central to first-line treatment, and choice among options depends on BRCA mutation and homologous recombination deficiency status. Recent guidance stresses marker-directed care, but head-to-head evidence across subgroups is limited. The team searched major libraries and meeting work for controlled trials in late-stage epithelial ovarian, fallopian tube, or primary peritoneal cancer. Their network analysis weighs efficacy and safety of the upkeep strategies.
Catalog record
| CREATOR | Juntao Feng, Xiaomei Qin, Xiaoliang Mo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |